Recent advances in the development of selective CB(2) agonists as promising anti-inflammatory agents.

Leleu-Chavain N, Body-Malapel M, Spencer J, Chavatte P, Desreumaux P, Millet R.

Source

Institut de Chimie Pharmaceutique Albert Lespagnol, Université Lille Nord de France, EA 4481, IFR114, 3 rue du Pr. Laguesse, B.P. 83, F-59006 Lille, France.

Abstract

The high distribution of CB(2) receptors in immune cells suggests their important role in the control of inflammation. Growing evidence offers this receptor as an attractive therapeutic target: CB(2) selective agonists are able to modulate inflammation without triggering psychotropic effects. This review will summarize the literature on the implication of CB(2) in inflammation and CB(2) selective agonists with anti-inflammatory activity.